

Masaru Kubota

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1854590/publications.pdf>

Version: 2024-02-01

18
papers

398
citations

1040056

9
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

642
citing authors

#	ARTICLE	IF	CITATIONS
1	MO272: Effect of the Hollow Fiber Diameter and Membrane Surface Area of the Polymethyl Methacrylate Membrane Filter Used in Continuous Renal Replacement Therapy on the Lifetime of the Filter. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
2	A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 8695-8705.	1.9	8
3	<p>Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4911-4921.	1.9	3
4	Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer. <i>Investigational New Drugs</i> , 2020, 38, 1906-1914.	2.6	7
5	Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors. <i>Investigational New Drugs</i> , 2020, 38, 885-893.	2.6	12
6	<p>Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4883-4892.	1.9	17
7	Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring <i>EGFR</i> Mutations. <i>Oncology</i> , 2018, 95, 109-115.	1.9	10
8	Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 6039-6047.	1.9	22
9	Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease. <i>Cancer Management and Research</i> , 2018, Volume 10, 7013-7019.	1.9	10
10	Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensiveâ€disease small cell lung cancer in the elderly and patients with poor performance status. <i>Thoracic Cancer</i> , 2018, 9, 967-973.	1.9	11
11	Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations. <i>Oncology Research and Treatment</i> , 2017, 40, 7-13.	1.2	9
12	Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 642-648.	2.6	5
13	Statement on New Reference Values for Spirometry. <i>Health Evaluation and Promotion</i> , 2017, 44, 687-692.	0.0	0
14	Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report. <i>Lung Cancer</i> , 2016, 99, 66-68.	2.0	15
15	Endobronchial involvement of mantle cell lymphoma: A case report. <i>Respiratory Medicine Case Reports</i> , 2016, 19, 77-79.	0.4	7
16	Secular Changes in Relative Leg Length Confound Height-Based Spirometric Reference Values. <i>Chest</i> , 2015, 147, 792-797.	0.8	37
17	Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values. <i>Respiratory Investigation</i> , 2014, 52, 242-250.	1.8	208
18	Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2010, 15, 447-452.	2.2	17